{"id":"W3093975417","doi":"10.1182/bloodadvances.2020002119","title":"Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase","year":2020,"lang":"en","type":"article","venue":"Blood Advances","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":72,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; Genentech; National Institutes of Health; Astellas Pharma; MacroGenics; Galecto; Sierra Oncology; CTI Biopharma; Incyte; Memorial Sloan-Kettering Cancer Center; Gilead Sciences; Cardinal Health; Amgen; Pfizer; PTC Therapeutics; Celgene; Eli Lilly and Company; AstraZeneca; Agios Pharmaceuticals","keywords":"Ruxolitinib; Decitabine; Medicine; Myeloproliferative neoplasm; Internal medicine; Phases of clinical research; Confidence interval; Population; Clinical endpoint; Oncology; Gastroenterology; Clinical trial; Myelofibrosis; Surgery; Bone marrow","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00006259696,0.0002532268,0.0006397184,0.000130669,0.00004114933,0.00001844585,0.00003941658,0.00004051585,0.00002127827],"category_scores_gemma":[0.00009133528,0.0001810776,0.00001520475,0.0003889357,0.00008318498,0.000229006,0.00003873626,0.0001497126,8.883671e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00001603408,"about_ca_system_score_gemma":0.0000538687,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000290566,"about_ca_topic_score_gemma":0.0002814398,"domain_scores_codex":[0.9985902,0.00006842171,0.0004224383,0.0004555101,0.0002400864,0.0002233077],"domain_scores_gemma":[0.9993249,0.000123415,0.0001318371,0.0001097867,0.0001223945,0.000187736],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.003572174,0.01916018,0.9592923,0.00009324877,0.0001343854,0.0001398662,0.005221583,0.0000104617,0.0001858219,0.00002518923,0.000003712289,0.01216109],"study_design_scores_gemma":[0.187052,0.03447437,0.7664463,0.0002664289,0.000201236,0.000008891214,0.002899601,0.0001743591,0.008070604,0.00001806247,0.0001396223,0.0002485457],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9970497,0.0007063018,0.000003566114,0.0003029663,0.00001339722,0.001711712,0.00005274433,0.00001616843,0.0001433874],"genre_scores_gemma":[0.9989551,0.0002064838,0.0004065148,0.0001829155,0.00002659425,0.0001589659,0.00003889301,0.00001837341,0.000006129419],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.192846,"threshold_uncertainty_score":0.7384131,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01948406931468189,"score_gpt":0.3019457263841157,"score_spread":0.2824616570694338,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}